group analysis. Odds ratios are now widely used and certainly very valuable for statistical analysis. For the interpretation of outcome data, the baseline, eg the remission rate of a standard treatment group, is very important. Similar odds ratios may be of different clinical relevance with different baselines. To give odds ratios as the main outcome measure may be misleading in some cases.
As has been stated in the discussion of our paper, all patients of study AML-BFM 87 were treated during induction with daunorubicin. Results for blasts in the bone marrow on day 15 are similar to the ADE arm of study AML-BFM 93. All patients of study AML-BFM 98 now receive idarubicin. Currently, results for the bone marrow blast count on day 15 (patients of study 98 diagnosed before June 2001) are similar to the AIE arm of study AML-BFM 93 (standard risk: 22% patients, high risk 18% patients with у5% blasts in the bone marrow). If we combine the data of studies AML-BFM 87, 93 and 98 for standard-risk patients, the percentage of patients with у5% blasts is 24% (43/181) after ADE and 19% (24/127, 95% CI 13-27%) after AIE. In the high risk group the percentage is 36% (93/257) after ADE and 17% (51/292) after AIE. The odds ratio is 0.75 (95% CI 0.43-1.3) for standard-risk and 0.37 (95% CI 0.25-0.55) for high-risk. The P-value of the test for heterogeneity is 0.046. Thus, the impact of AIE vs ADE on the bone marrow blast count on day 15 seems to be different in both risk groups also by the test proposed by Wheatley and Hills. Whether the reduction from 24% to 19% BM blasts in the SR-group should lead to clinical decisions is a matter of discussion. The longterm survival results of study AML-BFM 98 will help to give recommendations for the use of AIE in standard risk patients in pediatric AML.
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